It's obvious that the company has a good shot at returning to growth.One of the healthier stocks on the market Friday was veteran biotech Biogen (BIIB +8.82%). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both trailing and forward profitability. It was little wonder that impressed market players piled into the stock, leaving it with a nearly 9% gain on the day.Fine despite the declinesBiogen's fourth quarter saw the company book total revenue of almost $2 ...

百健预测 2026 年利润将高于华尔街平均预期，这表明大幅削减成本的措施正在缓解其多发性硬化症产品销售 额下降带来的影响。 百健公司(BIIB.US)于2月6日美股盘前公布2025年第四季度业绩以及未来业绩展望区间，最新数 据显示，管理层给出的2026年利润展望高于华尔街分析师平均预期，这表明大幅削减成本的举 措正在缓冲其多发性硬化症(MS)业务销售额萎缩带来的影响。 这家总部位于马萨诸塞州剑桥的生物科技公司在周五公布，预计今年经调整后的每股收益将介于 15.25美元至16.25美元之间，高于分析师平均预期。不过该公司管理层预计2026年整体营收将 以中个位数百分比下滑，使这项长期依赖MS治疗业务的经营压力延续。 砍成本与押注新产品双线齐力推进 首席执行官克里斯·维布拉赫(Chris Viehbacher)在业绩会议上接受分析师采访时表示，在努力 推动新产品增长数据的同时，百健在成本端保持了"极其严格的纪律"。自三年多前出任CEO以 来，他裁减了数百个岗位并不断宣布大幅降低开支的举措，其中部分措施包括将一些药物从研发 管线中彻底移除。 百健第四季度总营收规模约为23亿美元，同比小幅下滑7%，经调整后每股收益为 ...

Core Viewpoint - Biogen Inc. reported stronger-than-expected fourth-quarter 2025 results, leading to a more than 3% increase in shares, and provided an optimistic profit outlook for 2026 [1] Financial Performance - Adjusted earnings per share for Q4 2025 were $1.99, exceeding the analyst consensus of $1.61 [1] - Revenue for the quarter was $2.28 billion, surpassing expectations of $2.21 billion, although it represented a 7% decline year over year [1] Growth Products - Growth products showed positive momentum, with revenue increasing by 6% year over year in the quarter [2] - Global in-market sales of LEQEMBI reached approximately $134 million, marking a 54% year-over-year increase [2] - ZURZUVAE generated about $66 million in revenue, indicating strong demand growth [2] - SKYCLARYS expanded its global patient base by roughly 30% in 2025 [2] 2026 Outlook - For fiscal 2026, Biogen forecasts adjusted earnings per share in the range of $15.25 to $16.25, above the analyst consensus of $14.92 [3] - The company anticipates total revenue to decline by a mid-single-digit percentage compared to 2025, with expected declines in multiple sclerosis products, excluding VUMERITY, partially offset by growth in newer therapies [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Takeaways BIIB posted Q4 EPS of $1.99 and revenue of $2.28B, both beating estimates despite year-over-year declines.BIIB saw weakness in MS drugs and Spinraza, partly offset by growth from Leqembi, Skyclarys and Zurzuvae.BIIB guided 2026 adjusted EPS of $15.25-$16.25, above consensus, driving gains after the earnings release.Biogen (BIIB) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.99, which beat the Zacks Consensus Estimate of $1.61. Earnings declined 42% year over year.Total r ...

Biogen Leans Heavily Onto One Drug In Fourth-Quarter Beat | Investor's Business DailyBREAKING: [Dow Leads Stocks Higher As Nvidia, Goldman Sachs Rally]---Biogen (BIIB) narrowly topped Wall Street's fourth- quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri. But Tysabri's victory lap could be short-lived. In November, Sandoz launched its generic version of the multiple sclerosis drug in the U.S. Biosimilars have existed in Europe for years and Tysabr ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsChristopher A. Viehbacher - President and CEOPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and CFOTim Power - Head of Investor RelationsUmer Raffat - Senior Managing DirectorOperatorGood morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have bee ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsAlexandria Hammond - Director and Head of TherapeuticsBrian Abrahams - Managing Director and Co-Head of Biotechnology ResearchChris Schott - Managing DirectorChristopher A. Viehbacher - President and CEODanielle Brill - Managing DirectorEvan David Seigerman - Managing Director and Head of Healthcare ResearchMike Yee - Global Head of Biotechnology ResearchPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker1Good morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star 1 on your ...

Core Insights - Biogen reported a financial loss due to a significant decline in revenue from its primary multiple sclerosis treatments, indicating challenges in its core business operations [1] Company Performance - The company experienced a double-digit percentage decline in revenue from its multiple sclerosis treatments, which are crucial to its financial health [1]